After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?
SVR rates in recent DAA combination trials are really impressive. Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies. This begs the question: is there still room for improvement? Why Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?